Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand

Syndax Pharmaceuticals

04/08/2026 21:12

Overview
US cancer drugmaker's Q2 revenue rose 92% yr/yr on strong Revuforj and Niktimvo sales
Q2 net loss was higher than analyst expectations
Company expanded pipeline with new EGFR and menin inhibitors for NSCLC and myelofibrosis

Outlook
Company expects topline Phase 2 data for Niktimvo in IPF and cGVHD in 4Q26
Syndax maintains 2026 guidance for R&D plus SG&A expenses at about $400 mln, excluding $50 mln stock comp
Company expects IND submissions for SNDX-4321 and SNDX-62122 by end of 2026, with Phase 1 trials in 2027

Result Drivers
REVUFORJ PRESCRIPTION GROWTH - Co said Revuforj revenue rose on higher prescriptions and longer average treatment duration, especially in post-transplant setting
NIKTIMVO SALES - Niktimvo revenue increased, which co attributed to its unique mechanism of action in cGVHD and commercial opportunity
R&D SPENDING - Research and development expenses rose due to increased costs for frontline revumenib trials in AML

Company press release: ID:nGNX7x4MyV

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$49.36 mln
$39.41 mln (10 Analysts)
Q2 Cash & Investments
 
$575.10 mln
 
Q2 Operating Expenses
 
$112.78 mln
 
Q2 Operating Income
 
-$40 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $37.00, about 92.3% above its August 3 closing price of $19.24

Reuters Recommended Reads
Aug 3 - Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion
Aug 3 - Ireland's Jazz Pharma Q2 revenue beats estimates on Zepzelca higher sales
Aug 4 - Merck posts better-than-expected second-quarter results on Keytruda strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)